中国药物经济学
中國藥物經濟學
중국약물경제학
China Journal of Pharmaceutical Economics
2015年
10期
36-38
,共3页
类风湿关节炎%阿克他利%临床疗效%不良反应
類風濕關節炎%阿剋他利%臨床療效%不良反應
류풍습관절염%아극타리%림상료효%불량반응
Rheumatoid Arthritis%Actarit%Clinical Efficacy%Adverse reaction
目的:探讨阿克他利治疗类风湿关节炎患者的临床疗效。方法选取2013年7月至2014年6月武警德宏边防支队医院收治的类风湿关节炎患者资料70例,按随机数字表法将其分为对照组和观察组,各35例。对照组患者口服甲氨蝶呤片,观察组患者采用阿克他利治疗。比较两组患者的临床疗效。结果观察组患者总有效率为94.3%,明显高于对照组的77.1%,差异有统计学意义(P<0.05);治疗后两组患者各项症状指标均明显改善,差异均有统计学意义(均P<0.05);观察组患者的不良反应发生率为8.6%,明显低于对照组的31.4%,差异有统计学意义(P<0.05)。结论应用阿克他利治疗类风湿关节炎患者临床疗效明显,不良反应少。
目的:探討阿剋他利治療類風濕關節炎患者的臨床療效。方法選取2013年7月至2014年6月武警德宏邊防支隊醫院收治的類風濕關節炎患者資料70例,按隨機數字錶法將其分為對照組和觀察組,各35例。對照組患者口服甲氨蝶呤片,觀察組患者採用阿剋他利治療。比較兩組患者的臨床療效。結果觀察組患者總有效率為94.3%,明顯高于對照組的77.1%,差異有統計學意義(P<0.05);治療後兩組患者各項癥狀指標均明顯改善,差異均有統計學意義(均P<0.05);觀察組患者的不良反應髮生率為8.6%,明顯低于對照組的31.4%,差異有統計學意義(P<0.05)。結論應用阿剋他利治療類風濕關節炎患者臨床療效明顯,不良反應少。
목적:탐토아극타리치료류풍습관절염환자적림상료효。방법선취2013년7월지2014년6월무경덕굉변방지대의원수치적류풍습관절염환자자료70례,안수궤수자표법장기분위대조조화관찰조,각35례。대조조환자구복갑안접령편,관찰조환자채용아극타리치료。비교량조환자적림상료효。결과관찰조환자총유효솔위94.3%,명현고우대조조적77.1%,차이유통계학의의(P<0.05);치료후량조환자각항증상지표균명현개선,차이균유통계학의의(균P<0.05);관찰조환자적불량반응발생솔위8.6%,명현저우대조조적31.4%,차이유통계학의의(P<0.05)。결론응용아극타리치료류풍습관절염환자림상료효명현,불량반응소。
Objective To investigate the clinical efficacy of actarit in treatment of rheumatoid arthritis.Methods From July 2014 to June 2013, 70 patients with rheumatoid arthritis were randomly divided into control group and observation group by random number table method,35 cases in each group.The control group were treated with Methotrexate Tablets,observation group were treated by treatment of actarit.To compare the clinical efficacy of the two groups of patients.Results Difference was statisticaly significant in the observation group,the total efficiency of 94.3%,which was significantly higher than that in the control group 77.1%;two groups of patients with various sym- ptoms index were significantly improved after treatment,differences were statisticaly significant(P<0.05); observation group of patients with adverse reaction rate was 8.6%,significantly lower than the control group of 31.4%,the differe- nce is statisticaly significant (P<0.05).Conclusion Clinical application of actarit in treatment of rheumatoid arthritis significantly,less adverse reaction.